Latest Schedule 13G passive stakes

Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, reporting beneficial ownership of 450,315 shares, representing 9.99% of Imunon, Inc.'s common stock.

Aristeia Capital, L.L.C. has disclosed beneficial ownership of 5.24% of Maywood Acquisition Corp.'s Class A Ordinary Shares.

Armistice Capital, LLC and Steven Boyd have jointly reported beneficial ownership of 300,332 ordinary shares, representing 9.99% of IceCure Medical Ltd., as of June 30, 2026.

Eric M. Mindich has updated his beneficial ownership in Blue Moon Metals Inc. to 3.5% as of June 30, 2026, based on the latest outstanding share count.

Aristeia Capital, L.L.C. has reported beneficial ownership of 1,315,573 Class A ordinary shares, representing 5.20% of the outstanding shares of Inflection Point Acquisition Corp. VI.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 387,038 shares, representing 4.99% of GeoVax Labs, Inc. common stock.

Ameriprise Financial and Columbia Management report a combined 6.3% beneficial ownership of Diversified Energy Company common stock.

Ameriprise Financial and Columbia Management report a combined 6.3% beneficial ownership of Diversified Energy Company common stock.

Armistice Capital, LLC and Steven Boyd have jointly reported beneficial ownership of 9.99% of Global Interactive Technologies, Inc. common stock.

Aristeia Capital, L.L.C. has filed a Schedule 13G, reporting beneficial ownership of 4,840,477 shares of Hadron Energy, Inc. common stock, representing 6.59% of the outstanding shares.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 9.99% of Generation Income Properties, Inc. common stock as of June 30, 2026.

Aristeia Capital, L.L.C. has filed a Schedule 13G, disclosing beneficial ownership of 2,203,396 warrants in OppFi Inc., representing 2.52% of the class.

Aristeia Capital, L.L.C. has filed a Schedule 13G, revealing beneficial ownership of 652,725 units in FortuneX Acquisition Corporation, representing approximately 7.55% of the outstanding securities.

Armistice Capital, LLC and Steven Boyd report acquiring a 9.99% beneficial ownership in FibroBiologics, Inc. common stock.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 713,539 ordinary shares, representing 4.99% of Evogene Ltd.'s outstanding shares.

Aristeia Capital, L.L.C. has disclosed beneficial ownership of 1,350,000 units, representing 5.30% of Praetorian Acquisition Corp.'s outstanding shares as of June 30, 2026.

Aristeia Capital, L.L.C. has disclosed a beneficial ownership of 2,178,000 units, representing 8.61% of the outstanding shares of Collective Acquisition Corp. II.

Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, reporting beneficial ownership of 4.99% of Estrella Immunopharma, Inc. common stock.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, disclosing beneficial ownership of 9.99% of Enveric Biosciences, Inc. common stock.

Aristeia Capital, L.L.C. has filed a Schedule 13G, reporting beneficial ownership of 7.99% of ClearThink 1 Acquisition Corp.'s Class A ordinary shares as of June 30, 2026.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 3,384,798 shares, representing 9.99% of Dogwood Therapeutics, Inc.'s common stock.

Ameriprise Financial, Inc. and its subsidiaries, Columbia Management Investment Advisers, LLC and Columbia Small Cap Value Discovery Fund, have reported a combined beneficial ownership of 8.1% in Universal Electronics Inc. as of June 30, 2026.

Ameriprise Financial, Inc. and its subsidiaries, Columbia Management Investment Advisers, LLC and Columbia Small Cap Value Discovery Fund, have reported a combined beneficial ownership of 8.1% in Universal Electronics Inc. as of June 30, 2026.

Armistice Capital, LLC, through its Master Fund, has acquired a 9.99% stake in Decoy Therapeutics Inc., signaling a notable investment in the company's common stock.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 9,353,553 shares, representing 9.99% of Citius Oncology, Inc.'s common stock.

Madison Avenue International LP, along with affiliated entities, has reported a beneficial ownership of 9,212,252 ordinary shares, representing 17.7% of Theravance Biopharma, Inc.

Investment firm Armistice Capital, LLC, along with its managing member Steven Boyd, has reported beneficial ownership of 1,592,863 shares, representing 9.53% of CervoMed Inc.'s common stock.

Readystate Asset Management, LP and its affiliates have disclosed a beneficial ownership of 10.7% of Azul S.A.'s American Depositary Shares, representing a significant investment.

Ameriprise Financial, Inc. has amended its Schedule 13G filing to reflect changes in its beneficial ownership of Personalis, Inc. common stock.

Ameriprise Financial, Inc. has amended its Schedule 13G filing to reflect changes in its beneficial ownership of Personalis, Inc. common stock.